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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Bulgarian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data, and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 183 JIA patients (12% systemic, 53.6% oligoarticular, 23.5% RF negative polyarthritis, 
10.9% other categories) and 100 healthy children were enrolled in two centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. Notably, there is no significant difference between the healthy subjects and their affected 
peers in the school-related problems variable. All JAMAR components revealed good psychometric performances. In con-
clusion, the Bulgarian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Bulgarian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Bulgarian language.
Rheumatology
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from February 2012 
to June 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption (mean and standard deviation 
[SD] equivalence); the second Likert assumption or equal 
items-scale correlations (Pearson r: all items within a 
scale should contribute equally to the total score); third 
Likert assumption (item internal consistency or linear-
ity for which each item of a scale should be linearly 
related to the total score that is 90% of the items should 
have Pearson r ≥ 0.4); floor/ceiling effects (frequency of 
items at lower and higher extremes of the scales, respec-
tively); internal consistency, measured by the Cronbach’s 
alpha, interscale correlation (the correlation between two 
scales should be lower than their reliability coefficients, 
as measured by Cronbach’s alpha); test–retest reliability 
or intra-class correlation coefficient (reproducibility of 
the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR 
sub-scales with the 6 JIA core set variables, with the 
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addition of the parent assessment of disease activity and 
pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether 
the JAMAR discriminates between the different JIA cat-
egories and healthy children [18]. Quantitative data were 
reported as medians with first and third quartiles and cat-
egorical data as absolute frequencies and percentages.
The complete Bulgarian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Bulgarian JAMAR was fully cross-culturally adapted 
from the standard English version with 3 forward and 
2 backward translations with a concordance for 97/123 
translations lines (78.9%) for the parent version and 
115/120 lines (95.8%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). 
The parent and child versions of the Bulgarian JAMAR 
were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 200 JIA patients and 100 healthy children (total 
of 300 subjects) were enrolled at two paediatric rheumatol-
ogy centres. Seventeen patients did not give the consent to 
use their data.
In the remaining 183 JIA subjects, the JIA categories 
were 12% with systemic arthritis, 53.6% with oligoarthritis, 
23.5% with RF negative polyarthritis, 1.6% with RF posi-
tive polyarthritis, 1.6% with psoriatic arthritis, 4.9% with 
enthesitis-related arthritis, and 2.7% with undifferentiated 
arthritis (Table 1).
A total of 182/283 (64.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (136 from parents 
of JIA patients and 46 from parents of healthy children). The 
JAMAR was completed by 150/182 (82.4%) mothers and 
32/182 (17.6%) fathers. The child version of the JAMAR 
was completed by 167/283 (59%) children age 7.0 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first to third quartile)] obtained for the PF, 
the PhH, the PsH subscales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients. Notably, there is no sig-
nificant difference between the healthy subjects and their 
affected peers in the school-related problems.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing "Results" section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 0.7% (0–1.5%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 8 and 9, whereas a reduced 
number of response choices was used for all the PF items 
from 6 to 15.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
HRQoL items 1 and 4 (data not shown). The median number 
of items marked as not applicable was 0% (0–3%) for the PF 
and 8% (3–11%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 88.2% (55.1–95.6%) for the 
PF items, 36.8% (27.2–58.8%) for the HRQoL PhH items, 
and 75.7% (72.1–76.5%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0.7%) for the PF items, 
7.4% (3.7–8.8%) for the HRQoL PhH items, and 0.7% 
(0–2.2%) for the HRQoL PsH items. The median floor 
effect was 24.3% for the pain VAS, 22.8% for the disease 
activity VAS, and 28.7% for the well-being VAS. The 
median ceiling effect was 4.4% for the pain VAS, 2.2% 
for the disease activity VAS, and 2.2% for the well-being 
VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 90% of the HRQoL items, with the excep-
tion of item 1.
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 183 JIA patients. Data related to the JAMAR 
refer to the 136 JIA patients and to the 46 healthy subjects for whom the questionnaire has been completed by the parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy
*p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF − Poly-
arthritis
RF + Poly-
arthritis
Psoriatic 
Arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA patients Healthy
N = 22 N = 98 N = 43 N = 3 N = 3 N = 9 N = 5 N = 183 N = 100
Female 5 (22.7%) 59 (60.2%) 26 (60.5%) 3 (100%) 2 (66.7%) 1 (11.1%) 3 (60%) 99 (54.1%) 51 (51%)
Age at visit 9.7 (6.8–13.3) 10 (4.8–13.7) 12.9 
(7.5–15.9)
13.7 (10.9–
15.8)
16.9 
(7.7–16.9)
16.5 (15.7–
16.7)
7.1 (6.8–8.4) 11.9 (6–15.2)** 9.7 (5.6–
12.4)*
Age at onset 3.9 (1.9–6.9) 5.3 (2.1–9) 5 (2.2–9.7) 12.1 
(8.6–13.7)
13.2 
(5.3–14.1)
14.1 (13.2–
15.3)
5.6 (5.3–8.3) 5.4 (2.3–9.8)**
Disease duration 4.8 (2.1–8.5) 2.6 (1.2–5.6) 3.2 (1.9–10.1) 2.1 (1.6–2.3) 2.8 (2.4–3.7) 1.5 (0.6–6.5) 1.1 (0.1–1.2) 2.6 (1.3–6.5)*
ESR 14.5 (9–31) 16.5 (9–27) 22 (13–37) 12 (8–19) 43 (13–65) 20 (10–24) 77 (45–88) 18 (10–30)*
MD VAS 
(0–10 cm)
1 (0–3) 3 (2–4) 3 (2–5) – 5 (4–8) 5 (3–6) 4 (4–7) 3 (2–4)**
No. swollen joints 0 (0–2) 1 (1–2) 7 (3–13) 1 (1–14) 2 (2–10) 3 (0–4) 3 (2–6) 2 (1–4)#
No. joints with 
pain
2 (0–4) 1 (1–2) 4 (1–13) 1 (0–1) 2 (2–10) 4 (2–6) 2 (2–6) 2 (1–4)#
No. joints with 
LOM
0 (0–3) 1 (1–2) 7 (3–13) 1 (1–17) 2 (2–2) 3 (1–4) 3 (2–6) 2 (1–4)#
No. active joints 0.5 (0–3) 1.5 (1–2) 9 (4–14) 1 (1–14) 2 (2–10) 3 (1–4) 3 (2–6) 2 (1–4)#
Active systemic 
features
5 (22.7%) 0 (0%) 2 (4.7%) 0 (0%) 0 (0%) 0 (0%) 2 (40%) 9/181 (5%)
ANA status 0 (0%) 15 (15.3%) 10 (23.3%) 0 (0%) 1 (33.3%) 0 (0%) 1 (20%) 27 (14.8%)
Uveitis 0 (0%) 4/97 (4.1%) 5/42 (11.9%) 0 (0%) 0 (0%) 2 (22.2%) 0 (0%) 11/180 (6.1%)
PF Total Score 0 (0–1) 3 (1–4) 2 (0–8) 0 (0–0) 3 (0–4) 7 (3–10.5) 8 (7–10) 3 (0.5–5)* 0 (0–0)#
Pain VAS 0 (0–2) 4 (1–5.5) 1 (0–2.5) 0.5 (0.5–0.5) 4 (0.5–7) 8 (2.5–10) 6 (5–7) 3 (0.5–5)** 0 (0–0)#
Disease activity 
VAS
1 (0–2.5) 3 (1–5) 1.5 (0–3.5) 0 (0–0) 4 (0.5–8) 8 (2–9.3) 7 (7–8) 3 (0.5–5)*
Well-being VAS 1 (0–4) 3 (0–5) 1.3 (0–3) 0 (0–0) 3 (0–7.5) 7.5 (2.3–9.3) 5 (5–8) 2.3 (0–5)*
HRQoL PhH 1 (0–2) 3 (2–5) 2.5 (0–6) 1 (1–1) 2 (2–3) 5.5 (3–10) 3 (2–15) 3 (1–5)* 0 (0–0)#
HRQoL PsH 0 (0–1) 0 (0–1) 2.5 (0–4) 0 (0–0) 0 (0–0) 1.5 (0–4.5) 0 (0–0) 0 (0–2)* 0 (0–0)#
HRQoL total score 2 (1–3) 4 (2–6) 6.5 (1–13) 1 (1–1) 2 (2–3) 8 (6.5–12) 4 (2–15) 4 (2–7)* 0 (0–0)*
Pain/swell. in > 1 
joint
6/14 (42.9%) 70/87 (80.5%) 12/18 (66.7%) 1/1 (100%) 2 (66.7%) 6/8 (75%) 5 (100%) 102/136 (75%) 0 (0%)#
Morning stiff-
ness > 15 min
2/14 (14.3%) 16/87 (18.4%) 4/18 (22.2%) 0 (0%) 0 (0%) 4/8 (50%) 3 (60%) 29/136 
(21.3%)*
0 (0%)**
Subjective remis-
sion
5/14 (35.7%) 67/87 (77%) 10/18 (55.6%) 0 (0%) 2/2 (100%) 7/8 (87.5%) 5 (100%) 96/135 
(71.1%)*
In treatment 13/14 (92.9%) 69/87 (79.3%) 18/18 (100%) 1/1 (100%) 3 (100%) 6/8 (75%) 4 (80%) 114/136 
(83.8%)
Reporting side 
effects
2/13 (15.4%) 7/68 (10.3%) 4/18 (22.2%) 0 (0%) 0 (0%) 2/6 (33.3%) 1/4 (25%) 16/113 (14.2%)
Taking medication 
regularly
12/13 (92.3%) 64/68 (94.1%) 18/18 (100%) 1/1 (100%) 3 (100%) 6/6 (100%) 4/4 (100%) 108/113 
(95.6%)
With problems 
attending school
2/8 (25%) 1/53 (1.9%) 1/8 (12.5%) 0 (0%) 0 (0%) 1/6 (16.7%) 1/3 (33.3%) 6/82 (7.3%) 0 (0%)
Satisfied with dis-
ease outcome
13/14 (92.9%) 48/87 (55.2%) 14/18 (77.8%) 1/1 (100%) 2 (66.7%) 2/8 (25%) 2 (40%) 82/136 (60.3%)*
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Items internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 12) and 90% of items of the 
HRQoL (except for HRQoL item 1).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.91 for PF-LL, 0.92 for PF-HW, and 
0.72 for PF-US. Cronbach’s alpha was 0.87 for HRQoL–PhH 
and 0.94 for HRQoL–PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and 
wrist, PF-US PF-upper segment
Parent N = 136/182 Child N = 113/167
Missing values (First–third quartiles) 0.7% (0–1.5%) 0% (0–0.9%)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 88.2% 86.7%
 HRQoL PhH 36.8% 38.9%
 HRQoL PsH 75.7% 81.4%
 Pain VAS 24.3% 21.2%
 Disease activity VAS 22.8% 22.1%
 Well-being VAS 28.7% 23.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 7.4% 6.2%
 HRQoL PsH 0.7% 1.8%
 Pain VAS 4.4% 3.5%
 Disease activity VAS 2.2% 1.8%
 Well-being VAS 2.2% 4.4%
Items with equivalent item-scale correlation 100% for PF, 90% for HRQoL 100% for PF, 90% for HRQoL
Items with items-scale correlation ≥ 0.4 93% for PF, 90% for HRQoL 100% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.91 0.89
 PF-HW 0.92 0.91
 PF-US 0.72 0.83
 HRQoL–PhH 0.87 0.84
 HRQoL–PsH 0.94 0.88
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 1.0
 HRQoL–PhH 1.0 1.0
 HRQoL–PsH 1.0 1.0
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.6
 HRQoL PhH 0.5 0.6
 HRQoL PsH 0.1 0.3
 Pain VAS 0.4 0.3
 Disease activity VAS 0.3 0.4
 Well-being VAS 0.4 0.3
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
test–retest reliability
Reliability was assessed in 5 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 7 days (range 7–7 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed an almost 
perfect reproducibility (ICC = 1). The ICC for the HRQoL 
PhH and the ICC for the HRQoL PsH showed an almost 
perfect reproducibility (ICC = 1 for both).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.7 
(median = 0.6). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.3 to 0.7 (median = 0.5), whereas for the PsH ranged 
from − 0.02 to 0.1 (median = 0.1). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.7, 
p < 0.001), while the correlations of the PsH total score with 
the JIA core set of outcome variables were not significant. 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.4 (0.3–0.5), 0.3 
(0.3–0.5), and 0.4 (0.3–0.5), respectively.
Discussion
In this study, the Bulgarian version of the JAMAR was 
cross-culturally adapted from the original standard Eng-
lish version with 3 forward and 2 backward translations. 
According to the results of the validation analysis, the Bul-
garian parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. Notably, there was 
no significant difference between the healthy subjects and 
their affected peers in the school-related problems variable. 
This finding indicates that children with JIA adapt well to 
the consequences of JIA. The PF total score revealed to be 
able to discriminate between the different JIA subtypes with 
the children diagnosed with enthesitis-related arthritis and 
undifferentiated arthritis having a higher degree of disability, 
while the HRQoL total score proved to discriminate between 
the different JIA subtypes with children with enthesitis-
related arthritis having a poorer quality of life.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: 1 PF item (put hands 
behind the neck) and 1 HRQoL item (difficulty to take care 
of yourself) showed a lower items internal consistency. How-
ever, the overall internal consistency was good for all the 
domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong. Notably, the 
correlations of the PsH total score with the JIA core set of 
outcome variables were not significant.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, which 
suggests that children are equally reliable proxy report-
ers of their disease and health status as their parents. The 
JAMAR is aimed to evaluate the side effects of medications 
and school attendance, which are other dimensions of daily 
life that were not previously considered by other HRQoL 
tools. This may provide useful information for intervention 
and follow-up in health care. In conclusion, the Bulgarian 
version of the JAMAR was found to have satisfactory psy-
chometric properties and it is, thus, a reliable and valid tool 
for the multidimensional assessment of children with JIA.
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